|From: singhtelecom (Rep: 953)||Date: 02/09/2017 15:25|
|Forum: Stocks For A Different Jungle - Msg #19099 - List IDRA msgs ||Thread #673905685 (Rec: 0) |
|Dr. Yingling joins BIND from Bristol-Myers Squibb (BMS), where he was vice president, Oncology Discovery and Translational Research. During his tenure at BMS, he was responsible for the oncology research portfolio as well as translational capabilities in oncology and immunoscience, contributing to the discovery and development of potentially transformative medicines in immuno-oncology. He championed several small molecule drug discovery programs including IDO (indoleamine-2,3 dioxygenase), TGF-β and other important intracellular tumor cell targets. He also expanded the biologics portfolio with the addition of FS102, a novel anti-HER2 monoclonal antibody, and several proprietary antibody drug conjugate assets. |
Dr. Yingling began his pharmaceutical career as a senior biologist in oncology at Eli Lilly & Company in 2000. During his 13-year tenure, he served in various positions of increasing responsibility including CSO of Angiogenesis & Tumor Microenvironment Biology, Vice President of Oncology Research and Vice President of Translational Science and Technology. In those roles, he led innovative drug discovery programs focused on the tumor microenvironment, contributed to the expansion of Lilly’s oncology portfolio into targeted therapy and biologics culminating in the acquisition of ImClone in 2008 and integrated tailored therapeutic capabilities across Lilly Research Laboratories. As vice president of Translational Science and Technology, he led target enablement and screening, structural biology, fragment-based drug design and lead optimization biology capabilities across multiple therapeutic areas. Dr. Yingling earned his Ph.D. in Cell and Molecular Biology and Pharmacology at Duke University and was a Howard Hughes Postdoctoral Fellow at Vanderbilt University.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.